Everything tagged "biotech" across the TickerSpark archives.
argenx has turned VYVGART into a fast-growing, cash-generating immunology franchise with expanding label breadth and a deepening pipeline. The stock still trades at a premium, but the report argues the commercial momentum supports a Buy.
Moderna is a Hold as mNEXSPIKE gains traction and the pipeline advances, but shrinking revenue, heavy losses, and negative free cash flow keep the story high risk.
Insmed is transitioning from cash-burning biotech to a commercial respiratory growth story, powered by BRINSUPRI’s rapid launch and improving margins. The stock looks attractive on execution, but valuation already reflects meaningful success.
Elanco is showing real momentum from Zenrelia and Credelio Quattro, with 2026 guidance rising and organic growth improving across pet and farm animal lines. The stock still carries meaningful balance-sheet risk, so the upside case depends on execution and debt reduction.
Natera posted 39% Q1 revenue growth and continued rapid oncology and women’s health expansion, but losses and a rich valuation keep the stock at Hold. The report sees strong long-term clinical momentum, yet limited margin of safety at the current price.
BeOne Medicines is delivering strong oncology growth, led by BRUKINSA and expanding TEVIMBRA sales. The stock earns a Buy, but a premium valuation and product concentration keep the risk profile elevated.
Gilead’s HIV franchise is accelerating, with Yeztugo, Trodelvy, and a stronger pipeline offsetting pressure in Veklury and cell therapy. The stock looks attractive for moderate-risk investors with a medium-term horizon.
Krystal Biotech is now a profitable commercial biotech, driven by VYJUVEK’s rapid adoption and a deep pipeline of 2026 catalysts. The stock’s strong fundamentals are offset by a premium valuation, supporting a Hold view.
Axsome has evolved into a commercial CNS platform with rapid revenue growth, led by Auvelity and a newly expanded Alzheimer’s agitation opportunity. The stock still earns only a Hold as losses, leverage, and a rich valuation limit upside.
Sanofi combines strong Dupixent momentum, improving margins, and solid cash generation with a more leveraged balance sheet and a valuation that looks fair rather than cheap. The result is a patient Hold case for medium-term investors.
Twist Bioscience posted 19.3% revenue growth in fiscal Q2 2026 and raised full-year guidance, but it still faces losses and a demanding valuation. The stock earns a Hold as execution improves while investors wait for profitability.
Amgen’s portfolio is shifting toward faster-growing products like Repatha, EVENITY, and TEZSPIRE, but leverage and biosimilar erosion keep the stock in Hold territory. MariTide is the key medium-term catalyst, while Prolia and XGEVA remain the biggest drag.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the GeneratorCancel anytime